Immune checkpoint blockade (ICB) has become a standard treatment for non-small cell lung cancer (NSCLC). However. most patients with NSCLC do not benefit from these treatments. Abnormal vasculature is a hallmark of solid tumors and is involved in tumor immune escape. https://www.ceomelinh.com/product-category/washington-dc-2/